Hongji Wang
About Hongji Wang
Hongji Wang is a Senior Scientist at Bristol Myers Squibb with extensive experience in drug product development and a strong academic background in chemistry and pharmaceutical manufacturing.
Current Position at Bristol Myers Squibb
Hongji Wang is currently a Senior Scientist at Bristol Myers Squibb. In this role, Hongji applies extensive expertise in leading the development of Monoclonal Antibody (mAb), Antibody-Drug Conjugate (ADC), and Biologic-Device combination drug products from Investigational New Drug (IND) stages to Phase III clinical trials. Hongji is committed to advancing innovative therapies for patient care, leveraging a robust background in pharmaceutical sciences.
Previous Experience at NAL Pharmaceutical Group Limited
From 2017 to 2019, Hongji Wang worked as a Senior Formulation Scientist at NAL Pharmaceutical Group Limited in Monmouth Junction, NJ. During this time, Hongji refined skills in drug formulation and contributed to the advancement of pharmaceutical products. The position involved collaborating with cross-functional teams to optimize formulations and enhance the efficacy of drug products.
Career at Primera Analytical Solutions Corporation
Hongji Wang held a position as a Scientist at Primera Analytical Solutions Corporation in Princeton from 2015 to 2016. Over a 10-month period, Hongji focused on analytical research and contributed to the company's scientific endeavors in pharmaceutical analysis. The role included performing critical analytical tests and ensuring the accuracy and reliability of data.
Educational Background and Expertise
Hongji Wang earned a Ph.D. in Chemistry from Ludwig-Maximilians-Universität München, where studies took place from 2008 to 2013. Additionally, Hongji has a Master's Degree in Physical Chemistry from Nanjing University, completed from 2005 to 2008. Further complementing this strong academic foundation, Hongji obtained a second Master's Degree in Pharmaceutical Manufacturing from Stevens Institute of Technology from 2015 to 2016. This dual Master's background underpins Hongji's expertise in leading complex drug product developments.
Specialization in Drug Product Development
Hongji Wang specializes in the development of Monoclonal Antibody (mAb), Antibody-Drug Conjugate (ADC), and Biologic-Device combination drug products. With a focus on taking projects from IND submission through to Phase III clinical trials, Hongji combines an academic background in chemistry and pharmaceutical manufacturing with extensive industry experience. This specialization is critical for advancing therapeutic innovations and improving patient care outcomes.